TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05950061
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (200 mg/day) capsule
Study: NCT05950061
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram (10 mg/day) capsule
Study: NCT04453085
Drug: JR-171 (lepunafusp alfa)
Normalized name: Lepunafusp alfa
DrugBank: Lepunafusp alfa (DB19011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06344052
Drug: Vismodegib
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The HHPI vismodegib is currently indicated for the treatment of adult patients with metastatic BCC, or with laBCC where surgery and/or radiation therapy are not appropriate.
Study: NCT05438602
Drug: Nirmatrelvir
Normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive 2 tablets of nirmatrelvir every 12 hours
Study: NCT05438602
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive 1 capsule of ritonavir every 12 hours
Study: NCT05438602
Drug: Placebo for nirmatrelvir
Normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive 2 tablets of placebo for nirmatrelvir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
Study: NCT05438602
Drug: Placebo for ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive 1 capsule of placebo for ritonavir every 12 hours. A placebo does not have any medicine in it but looks just like the medicine being studied.
Study: NCT05275010
Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab SC (PH FDC SC)
Normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose of PH FDC SC (600 mg pertuzumab/600 mg trastuzumab) will be administered by a healthcare professional subcutaneously (SC) into the anterior thigh, using either a handheld syringe with hypodermic needle (Arm 1) or the on-body delivery system (Arm 2).
Study: NCT00000981
Drug: Fiacitabine
Normalized name: Fiacitabine
DrugBank: Fiacitabine (DB12901)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06537297
Drug: Intrathecal Pemetrexed and high-dose Furmonertinib plus bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly;~* Furmonertinib(160mg QD);~* bevacizumab(5mg/kg，once monthly) until progressive disease.
Study: NCT06333522
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive Losartan 12.5mg orally twice daily beginning 2 weeks preoperatively and continuing for 4 weeks postoperatively.
Study: NCT06035393
Drug: Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation
Normalized name: glycopyrronium / indacaterol
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug 3
Study: NCT06035393
Drug: Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation
Normalized name: glycopyrronium / indacaterol
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug 4
Study: NCT04863248
Drug: Trilaciclib
Normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trilaciclib administered IV over 30 minutes prior to docetaxel IV on Day 1 of each 21-day cycle.
Study: NCT04863248
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel administered IV on Day 1 of each 21-day cycle.
Study: NCT05447702
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT05447702
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: po.
Study: NCT05447702
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion.
Study: NCT05447702
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion.
Study: NCT05948228
Drug: Fluoride gel
Normalized name: Sodium Fluoride Gel
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Application of fluoride gel to prevent white spot lesions in orthodontic patients
Study: NCT06126640
Drug: SHR-A1811
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized powder injection, 100mg / bottle, intravenous drip
Study: NCT05154136
Drug: Etrumadenant
Normalized name: Etrumadenant
DrugBank: Etrumadenant (DB17506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT05154136
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule
Study: NCT06126640
Drug: Trastuzumab Emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lyophilized powder injection, 160mg / bottle, 100mg / bottle, intravenous drip
Study: NCT06065059
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PARP inhibitor
Study: NCT05801757
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Using two different doses of remidazolam for continuous pumping to maintain anesthetic effect
Study: NCT05801757
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol 2-3mg/kg/h
Study: NCT00002211
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002211
Drug: Delavirdine mesylate
Normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002211
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002211
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04695054
Drug: Only EMLA cream
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream will be applied 60 minutes before the needle procedure
Study: NCT04219319
Drug: Efficacy of LCAR-T2C CAR-T cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD4-directed CAR-T cells administered with lymphodepletion, and to obtain the preliminary efficacy results in subjects who have been diagnosed with relapsed or refractory CD4 positive T lymphocyte tumor
Study: NCT05403242
Drug: RC48-ADC
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.0 mg/kg, IV, d1, every 2 weeks; or 2.5 mg/kg, IV, d1, every 2 weeks
Study: NCT05403242
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 40-60 mg, bid po, d1-10, every 2 weeks
Study: NCT05764304
Drug: Sinomenine
Normalized name: Sinomenine
DrugBank: Sinomenine (DB16892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive one intra-articular injection every 4 months
Study: NCT04480190
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Gemcitabine 1000mg/m2 to be given on Days 1, Day 8 (Before Cisplatin); 3 week cycles
Study: NCT04480190
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Cisplatin 25mg/m2 to be given on Days 1, Day 8
Study: NCT04829799
Drug: 1% preservative-free lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Instillation of intracameral lidocaine after initial paracentesis incision.
Study: NCT01045941
Drug: Gemcitabine/Gemzar
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Six cycles of Gemcitabine will be given. Each cycle of Gemcitabine comprises of Gemcitabine 1000 mg/m2 as a 30 minute infusion once weekly for 3 weeks with a fourth week off.
Study: NCT05410847
Drug: Camrelizumab Nab-Paclitaxel S-1
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Camrelizumab+S-1+Intraperitoneal nab-paclitaxel and intravenous nab-paclitaxel
Study: NCT01983722
Drug: Stiripentol
Normalized name: Stiripentol
DrugBank: Stiripentol (DB09118)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05848700
Drug: SEP-363856
Normalized name: SEP-363856
DrugBank: SEP-363856 (DB15665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEP-363856 Tablet
Study: NCT05946785
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
Study: NCT05783076
Drug: adoptive cell therapy with vNKT cells
Normalized name: hRPE cell therapy
DrugBank: ASP-7317 (DB18549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Details have been shown in arm descriptions.
Study: NCT05068063
Drug: Bupivacaine Injection
Normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided Femoral Triangle block with 20 mL of Bupivacaine 0.25% and IPACK block with 20 mL of Bupivacaine 0.25%
Study: NCT06219837
Drug: bupivacaine injection by ultrasound guided transversalis fascia plane block
Normalized name: Ivy Block
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: With patients in a sitting position and after appropriate skin asepsis, a 25-G pencil-point spinal needle (Pencil Point Spinal Needle Set, Egemen International Ltd., Izmir, Turkey) will be inserted through the L3 to L4 or L4 to L5 intervertebral space and 15 mg of 0.5% hyperbaric bupivacaine (AstraZeneca Pharmaceuticals, Cambridge, United Kingdom) will be injected. Subsequently, the patients will be positioned supine.
Study: NCT06311890
Drug: N-chlorin e6 triglumine
Normalized name: Chlorin e6
DrugBank: Phytochlorin (DB19265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a photodynamic therapy with chlorin-e6
Study: NCT05451173
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: an anti-PD-(L)1 immune checkpoint inhibitor is administered concurrently and adjuvantly with radiotherapy.
Study: NCT05553977
Drug: Bowel preparation for colonoscopy
Normalized name: cranberry preparation
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one day liquid diet will be administered to every patient included in the study and: split-dose bowel preparation with 4 Liters of Polyethylene glycol solution, 2 Liters of PEG-Ascorbic acid or 2 Liters Picosulfate.
Study: NCT04656041
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).
Study: NCT04656041
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).
Study: NCT04942340
Drug: Dexmedetomidine Hydrochloride & Saline
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In this arm, subjects will be infused with Precedex \& Saline at 15 mg/kg across 5 minutes
Study: NCT06385093
Drug: Eldecalcitol capsules
Normalized name: Decalcitrol
DrugBank: Eldecalcitol (DB05295)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral eldecalcitol 0.75μg daily
Study: NCT06385093
Drug: Alfacalcidol tablets
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Alfacalcidol 0.5μg daily
Study: NCT06385093
Drug: Calcium carbonate tablets
Normalized name: Calcium Carbonate Tablets
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5g Calcium carbonate daily
Study: NCT06395402
Drug: Lutetium Lu 177 dotatate therapy
Normalized name: Lutetium dotatate Lu-177
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUTATHERA is an FDA approved radiopharmaceutical therapy for gastroenteropancreatic neuroendocrine tumor (GEP-NET). This radiopharmaceutical binds to somatostatin receptors, which are overexpressed on GEP-NET cells, and subsequently delivers beta particle radiation to the tumor cells.
Study: NCT06414148
Drug: Epcoritamab
Normalized name: Epcoritamab
DrugBank: Epcoritamab (DB16672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epcoritamab will be administered as a 28-day cycle. In Cycle 1 and 2, epcoritamab will be given with step up dosing in Cycle 1. From Cycle 3 onwards dosing will be on Day 1 and 15 of each cycle.
Study: NCT06414148
Drug: Epcoritamab, lenalidomide and rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with epcoritamab will be administered following the same dosing schedule as Arm A. On days where rituximab and/or lenalidomide are also due, epcoritamab should be administered last.~Patients will receive lenalidomide once daily on Day 1-21 of each 28-day cycle, starting at Cycle 1 through to Cycle 6.~Patients will receive rituximab administered by intravenous (IV) infusion on Day 1, 8, 15 and 22 of Cycle 1 and on Day 1 only of Cycles 2-6.
Study: NCT06506032
Drug: Intravenous Vancomycin administration
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin was administered to the patients at the discretion of the physician
Study: NCT05173688
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The low maintenance dose propofol group was maintained at 4-6 mg/kg/h ；and The high maintenance dose propofol group was maintained at 8-12 mg/kg/h
Study: NCT06337474
Drug: anti-CD19 CAR NK cells (KN5501)
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (1000mg/m2 per day) on day -3. Doses of 9×10\^9 cells, 13.5×10\^9 anti-CD19 CAR NK cells (KN5501) will infused in each group using the dose-escalation strategy
Study: NCT04316611
Drug: Potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Direct intravenous injection (IVD) 20 mmol potassium chloride
Study: NCT06157541
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) specific for the programmed cell death 1 (PD-1) receptor
Study: NCT05981079
Drug: Piperacillin/tazobactam
Normalized name: PIPERACILLIN/TAZOBACTAM
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperacillin Sodium and Tazobactam Sodium for Injection
Study: NCT06201793
Drug: Mesalazine
Normalized name: mesalazine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis
Study: NCT00004552
Drug: acamprosate (Campral)
Normalized name: acamprosate calcium Delayed Release Oral Tablet [Campral]
DrugBank: Acamprosate (DB00659)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06223256
Drug: NBL-028
Normalized name: NBL-015
DrugBank: NBL-015 (DB18183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion (IV), once every two weeks (one treatment cycle is 4 weeks).
Study: NCT04881929
Drug: KN026
Normalized name: ANTI-HER2 BSAB KN026
DrugBank: Anbenitamab (DB18411)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KN026 in Combination With Docetaxel
Study: NCT05986968
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor monotherapy for 12 months
Study: NCT05986968
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (aspirin plus ticagrelor) for 12 months
Study: NCT05146713
Drug: sodium hypochlorite
Normalized name: Sodium hypochlorite
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5% sodium hypochlorite (household bleaching agent)
Study: NCT06478797
Drug: Adrenalin
Normalized name: Adrenalin
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sepsis will be treated with early inotropes, where participants will receive adrenaline at a dose of 0.05 - 0.1 mcg/kg/min via peripheral intravenous, intraosseous, or central venous routes after the first fluid bolus of 20 ml/kg
Study: NCT06669091
Drug: Ecopipam tablet
Normalized name: Ecopipam
DrugBank: Ecopipam (DB12273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single ecopipam 89.6 mg tablet (equivalent to ecopipam HCl 100 mg)
Study: NCT04889768
Drug: HIPEC, anti-PD-1 antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. HIPEC: Taxol (Paclitaxel Injection) 75 mg/m2, d1, d3 within 72 hours after surgical exploration; oral chemotherapy:S-1: 80mg/m2, twice daily for d1-d14, and then suspend for one week; Intravenous drip anti-PD-1 antibody Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~2. Chemotherapy and PD-1 treatment (4 cycles) : Taxol 150mg/m2,d1; S-1: 80-120mg/m2, twice daily for two weeks, and then suspend for one week; Camrelizumab (SHR-1210) 200mg fixed dose every 3 weeks.~3. Surgery: Secondary surgical exploration: if PCI less than 20, then assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases ). For inoperable patients, continue to use this program for treatment.~4. After the surgery, HIPEC for two cycles, anti-PD-1 antibody Camrelizumab (SHR-1210) for 4 cycles, and PS chemotherapy for 4 cycles.
Study: NCT05179603
Drug: THOR-707
Normalized name: IL-2 variant THOR-707
DrugBank: Pegenzileukin (DB17495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
Study: NCT05179603
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
Study: NCT06399185
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine 0.5 μg/kg, diluted with normal salinet o 20 ml, is infused intravenously at 60 ml/h after anesthesia induction but before surgery.
Study: NCT06399185
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine 0.25 mg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
Study: NCT06399185
Drug: Combined dexmedetomidine-esketamine
Normalized name: esketamine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dexmedetomidine 0.5 μg/kg and esketamine 0.25 mg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
Study: NCT06668961
Drug: SI-B001
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion
Study: NCT06668961
Drug: SI-B003
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion
Study: NCT06669611
Drug: Camrelizumab combined GP chemotherapy
Normalized name: Ocrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab was intravenously given at dose of 200 mg on day 1. The GP regimen included gemcitabine administered at a dose of 1 g/m2 on day 1 and day 8, cisplatin at a dose of 80 mg/m2 on day 1.Q3W 1 cycle, 4-6 cycles.
Study: NCT06669611
Drug: Camrelizumab combined TPC chemotherapy
Normalized name: Ocrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab was intravenously given at dose of 200 mg on day 1. The TPC regimen included nab-paclitaxel administered at a dose of 200 mg/m2 on day 1, cisplatin at a dose of 60 mg/m2 on day 1, and capecitabine at a dose of 1000 mg/m2, taken orally twice a day on days 1 to 14, for each cycle. Q3W 1 cycle, 4-6 cycles.
Study: NCT06670976
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06604286
Drug: In this group, patients received 8 mg IM dexamethasone injection into the masseter muscle after impacted tooth surgery.
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8 mg IM dexamethasone injection was given to the groups immediately after the operation area was sutured after impacted dental surgery. Dexamethasone injection in group 1 was made into the masseter muscle. injection; The margo anterior of the mandible was palpated and horizontally parallel to the occlusal level of the mandibular second molar tooth and 1 cm behind the margo anterior towards the mandibular ramus. Bone contact was not taken during the injection and the injection was made by taking negative aspiration.
Study: NCT06604286
Drug: 8 mg IM dexamethasone injection into the pterygoid cavity after impacted tooth surgery.
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8 mg IM dexamethasone injection was given to the group immediately after the operation area was sutured after impacted dental surgery. Dexamethasone injection given to Group 2 was directed to the region between the margo anterior of the mandible and the raphe pterygomandibularis, 1 cm above the occlusal level of the mandibular 2nd molar tooth, and the direction of the syringe from the incisal top of the opposing mandibular canine tooth to this region, and then entering the pterygomandibular cavity.